March 28, 2025 03:35 PM EDTUpdated March 31, 05:42 PM

Judge tosses Amgen's challenge to Colorado drug review board, says suit is 'too speculative'

Nicole DeFeudis

Editor

A federal judge on Friday dismissed Amgen’s lawsuit against Colorado’s drug affordability board and its call for a price cap on the company’s blockbuster autoimmune …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Judge tosses Amgen's challenge to Colorado drug review board, says suit is 'too speculative'

Nicole DeFeudis

Editor

Sign up to read this article for free.

Firings sweep across FDA as former leaders lament the gutting of drug agency

RFK Jr. has long criticized drug ads. He just slashed the FDA office that regulates them

‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul

Sanofi continues its bet on R&D by poaching GSK’s head of development

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Judge toss­es Am­gen's chal­lenge to Col­orado drug re­view board, says suit is 'too spec­u­la­tive'

Nicole DeFeudis

Editor

Sign up to read this article for free.

Fir­ings sweep across FDA as for­mer lead­ers lament the gut­ting of drug agency

RFK Jr. has long crit­i­cized drug ads. He just slashed the FDA of­fice that reg­u­lates them

‘It’ll be a chal­lenge’: BIO chief Crow­ley ad­dress­es seis­mic FDA over­haul

Sanofi con­tin­ues its bet on R&D by poach­ing GSK’s head of de­vel­op­ment

Big am­bi­tions at Mer­ck and As­traZeneca — along with a few gi­ant pit­falls — re­shape top ranks of the R&D 15

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

Judge tosses Amgen's challenge to Colorado drug review board, says suit is 'too speculative'

Firings sweep across FDA as former leaders lament the gutting of drug agency

RFK Jr. has long criticized drug ads. He just slashed the FDA office that regulates them

‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul

Sanofi continues its bet on R&D by poaching GSK’s head of development

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO